uPAR – the Target
uPAR (urokinase-type plasminogen activator receptor) is a unique, validated biomarker of aggressive cancer, as it is a key functional driver of invasion, angiogenesis, and metastasis, and is highly upregulated across most aggressive solid tumors while showing limited expression in normal tissue. These characteristics make uPAR an ideal target for radioligand therapy.
Curasight is advancing uTREAT® a first-in-class uPAR-targeted radioligand therapy platform for multiple solid tumors. uTREAT®, is supported by uTRACE® - a clinically validated uPAR PET diagnostic platform built on the same uPAR-targeting ligand. uTRACE® enables a true theranostic approach by supporting patient selection, confirming tumor targeting, and de-risking therapeutic development through human imaging validation.
uPAR is clinically validated as a potent RLT target with uTRACE® in nine clinical trials (450 patients) across eight different cancer types. Curasight’s uPAR technology platform is fully developed, GMP-manufactured, with a commercial supply infrastructure in place.
One target. One ligand. See it. Treat it. Track it.
uPAR Theranostics
Curasight's novel and innovative Theranostics platform for improved cancer diagnose and treatment.
Nuclear medicine in brief
Nuclear medicine involves the application of radioactive substances in the diagnosis and treatment of disease. This is done by recording radiation emitting from within the body. This differs from external radiation, where images are generated by external sources of energy such as X-rays. Often nuclear medicines can treat parts of the body where traditional external radiation is not useful as vital organs and healthy tissue around the cancer is also radiated. That is the limitation of traditional external radiation.
